Ticker
INMCompany Name
INMED PHARMACEUTICALS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Depreciation, Amortization & Accretion | Earning Before Interest & Taxes (EBIT) | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) |
---|---|---|---|
6/30/2025 | $ 534.72K | $ -7.79M | $ -7.26M |
3/31/2025 | $ 555.5K | $ -7.95M | $ -7.4M |
12/31/2024 | $ 576.61K | $ -7.55M | $ -6.98M |
9/30/2024 | $ 600.13K | $ -6.81M | $ -6.21M |
6/30/2024 | $ 604.52K | $ -7.67M | $ -7.06M |
3/31/2024 | $ 603.63K | $ -6.07M | $ -5.47M |
12/31/2023 | $ 602.11K | $ -6.35M | $ -5.75M |
9/30/2023 | $ 596.85K | $ -6.97M | $ -6.37M |
6/30/2023 | $ 596K | $ -7.93M | $ -7.34M |
3/31/2023 | $ 599.09K | $ -15.47M | $ -14.87M |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
EBIT + DepAmor
(=) EBITDA
EBITDA for INMED PHARMACEUTICALS INC is calculated as follows: EBIT [ $ -9.84M ] + DepAmor [ $ 228.69K ]
(=) EBITDA [ $ -9.61M ]
Minimum
Sep 30, 2022
Maximum
Mar 31, 2024
Average
Median
filtered constituents | 3.24K |
---|---|
min | $ -493.3M |
max | $ 590.6M |
average | $ 58.9M |
median | $ 8.92M |
std | $ 167.01M |